Objective: This study was undertaken to evaluate the role of secondary cytoreduction in patients with recurrent epithelial ovarian cancer. Study design: Secondarily, cytoreduced patients were retrospectively analyzed with respect to the clinicopathologic variables. Results: A total of 64 patients were evaluated in this report. Multivariable analysis revealed 3 factors to be significant: optimal cytoreduction during primary (P = .003, odds ratio [OR]: 0.30; 95%CI: 0.14-0.66), secondary cytoreduction (P = .04, OR: 0.47; 95%CI: 0.22-0.99), and the endometrioid histologic type (P = .005, OR: 0.09; 95%CI: 0.02-0.48). Intrinsic factors of the tumors (grade, stage, age), size, and number of recurrent tumors were nonsignificant. Conclusion: Secondary cytoreductive surgery should be offered in selected recurrent epithelial ovarian cancer patients. Further prospective randomized series are needed to determine specific recommendations. Objective: This study was undertaken to evaluate the role of secondary cytoreduction in patients with recurrent epithelial ovarian cancer. Study design: Secondarily, cytoreduced patients were retrospectively analyzed with respect to the clinicopathologic variables. Results: A total of 64 patients were evaluated in this report Multivariable analysis revealed 3 factors to be significant: optimal cytoreduction during primary (P = .003, odds ratio [OR]: 0.30; 95% CI: 0.14-0.66), secondary cytoreduction % CI: 0.22-0.99), and the endometrioid histologic type (P = .005, OR: 0.09; 95% CI: 0.02-0.48). Intrinsic factors of the tumors (grade, stage, age) recurrent tumors were nonsignificant. Conclusion: Secondary cytoreductive surgery should be offered in selected recurrent epithelial ovarian cancer patients. Further prospective randomized series are needed to determine specific recommendations.